PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

REC'D 11 MAY 2004

(PCT Article 18 and Rules 43 and 44)

| Applicant's or agent's file reference 12424680/TDO/FT | FOR FURTHER ACTION | see Form PCT/ISA/220 as well as, where applicable, item 5 below. | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|--|--|--|--|
| International application No. PCT/AU2004/000336 | 1034 1000 | | | | | |
| Applicant MEDVET SCIENCE PTY. L | ΓD. et al | | | | | |
| This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau. | | | | | | |
| This international search report consists of a | total of 5 sheets. | · | | | | |
| It is also accompanied by a cop | py of each prior art document cited in | this report. | | | | |
| 1. Basis of the report | | | | | | |
| With regard to the language, the integrated it was filed, unless otherwise indicated | ernational search was carried out on the dunder this item. | he basis of the international application in the language in which | | | | |
| Authority (Rule 23.1) | (b)). | ranslation of the international application furnished to this | | | | |
| b. With regard to any nucleotide | and/or amino acid sequence disclos | ed in the international application, see Box No. I. | | | | |
| 2. X Certain claims were found up | nsearchable (See Box No. II). | | | | | |
| 3. Unity of invention is lacking | (See Box No. III). | | | | | |
| 4. With regard to the title, | • | | | | | |
| the text is approved as submitt | ed by the applicant. | | | | | |
| <u> </u> | y this Authority to read as follows: | | | | | |
| A method of modulating sm signalling | ooth muscle cell functioning | by modulating sphingosine kinase mediated | | | | |
| ·. | • | | | | | |
| 5. With regard to the abstract, | | | | | | |
| X the text is approved as submitted | ted by the applicant. | | | | | |
| the text has been established. | according to Rule 38.2(b), by this Au | thority as it appears in Box No. IV. The applicant may, within ort, submit comments to this Authority. | | | | |
| 6. With regard to the drawings, | · | | | | | |
| a. the figure of the drawings to be put | blished with the abstract is Figure No. | | | | | |
| as suggested by the a | applicant. | | | | | |
| as selected by this A | uthority, because the applicant failed | to suggest a figure. | | | | |
| as selected by this Authority, because this figure better characterizes the invention. | | | | | | |
| b. X none of the figures is to be pu | blished with the abstract. | | | | | |

International application No. PCT/AU2004/000336

| | | ······································ | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|-----------------------|--|--|--|--|
| A. | CLASSIFICATION OF SUBJECT MATTER | | | | | | |
| Int. Cl. 7: | C12Q 1/48 | | | | | | |
| According to | International Patent Classification (IPC) or to both n | ational classification and IPC | | | | | |
| В. | FIELDS SEARCHED | | | | | | |
| SEE ELECT | mentation searched (classification system followed by cla RONIC DATABASE BOX BELOW | | | | | | |
| | searched other than minimum documentation to the exter RONIC DATABASE BOX BELOW | t that such documents are included in the fields search | ned . | | | | |
| CA, MEDL | base consulted during the international search (name of d NE, WPIDS: Keywords: smooth muscle, sphing hibit, express. | ata base and, where practicable, search terms used) gosine, RhoA, Rho kinase, signal transduction | on, regulate, | | | | |
| C. | DOCUMENTS CONSIDERED TO BE RELEVANT | | | | | | |
| Category* | Citation of document, with indication, where appr | opriate, of the relevant passages | Relevant to claim No. | | | | |
| P, X | Bolz S-S et al. (2003) Circulation 108: 342-347. "Sphingosine kinase modulates microvascular tone and myogenic responses through activation of RhoA/Rho kinase", X See whole document. | | | | | | |
| P, X | Dantas A P V et al. (2003) Am J Physiol Heart Circ Physiol 284: H2045-H2052. "Sphingosine 1-phosphate and control of vascular tone". See whole document. | | | | | | |
| Р, Х | 1-27 and 45- 49 | | | | | | |
| . Х н | Further documents are listed in the continuation | of Box C See patent family annu | ex | | | | |
| * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention | | | | | | | |
| "E" earlier application or patent but published on or after the international filing date "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone | | | | | | | |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art | | | | | | | |
| "O" docume or other | | | | | | | |
| but late | "P" document published prior to the international filing date but later than the priority date claimed | | | | | | |
| | ual completion of the international search | Date of mailing of the international search report 4 MAY 2004 | | | | | |
| 28 April 200 Name and mai | ing address of the ISA/AU | Authorized officer | | | | | |
| AUSTRALIAN PATENT OFFICE | | | | | | | |
| PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au JANE MCHENRY | | | | | | | |
| Facsimile No. | (02) 6285 3929 | Telephone No : (02) 6283 2091 | | | | | |

International application No.
PCT/AU2004/000336

| Citation of document, with indication, where appropriate, of the relevant passages Remove spaces when completed if the page is too long) olly P S et al. (2001) Mol Immunol 38: 1239-1245. "The roles of sphingosine-1- phosphate in asthma" See whole document, especially figures 1 and 4 Ammit A J et al. (2001) FASEB J 15: 1212-1214. "Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma" See whole document. Wettschureck N & Offermanns S (2002) J Mol Med 80: 629-638. "Rho/Rho-kinase mediated signalling in physiology and pathophysiology" See whole document. Bitar K N & Yamada H. (1995) Am J Physiol 269: G370-G377. "Modulation of | 1-27 and 45-49 1-27 and 45-49 1-19, 25 and 26 |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|
| olly P S et al. (2001) Mol Immunol 38: 1239-1245. "The roles of sphingosine-1- shosphate in asthma" See whole document, especially figures 1 and 4 Ammit A J et al. (2001) FASEB J 15: 1212-1214. "Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma" See whole document. Wettschureck N & Offermanns S (2002) J Mol Med 80: 629-638. "Rho/Rho-kinase mediated signalling in physiology and pathophysiology" See whole document. Bitar K N & Yamada H. (1995) Am J Physiol 269: G370-G377. "Modulation of | 1-27 and 45-49 |
| modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma" See whole document. Wettschureck N & Offermanns S (2002) J Mol Med 80: 629-638. "Rho/Rho-kinase mediated signalling in physiology and pathophysiology" See whole document. Bitar K N & Yamada H. (1995) Am J Physiol 269: G370-G377. "Modulation of | |
| nediated signalling in physiology and pathophysiology" See whole document. Bitar K N & Yamada H. (1995) Am J Physiol 269: G370-G377. "Modulation of | 1-19, 25 and 2 |
| Bitar K N & Yamada H. (1995) Am J Physiol 269: G370-G377. "Modulation of | |
| smooth muscle contraction by sphingosylphosphorylcholine" See whole document. | 1-27 and 45-4 |
| Waters C et al. (2003) J Biol Chem 278(8): 6282-6290. "Sphingosine 1-phosphate and platelet-derived growth factor (PDGF) act via PDGFβ receptor-sphingosine 1-phosphate receptor complexes in airway smooth muscle cells" See whole document. | |
| | |
| | |
| | |

International application No.

PCT/AU2004/000336

| Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet) | | | | |
|------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|
| This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: | | | | |
| 1. | Claims Nos.: | | | |
| | because they relate to subject matter not required to be searched by this Authority, namely: | | | |
| 2. X | Claims Nos.: 27-44 and 50-52 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: See supplementary box below. | | | |
| | | | | |
| 3. | Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a) | | | |
| | | | | |
| Box No. II | | | | |
| This Intern | ational Searching Authority found multiple inventions in this international application, as follows: | | | |
| | | | | |
| | | | | |
| | | | | |
| 1. | As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. | | | |
| 2. | As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite | | | |
| | payment of any additional fee. | | | |
| 3. | As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: | | | |
| 4. | No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: | | | |
| Remark o | n Protest The additional search fees were accompanied by the applicant's protest. | | | |
| | No protest accompanied the payment of additional search fees. | | | |
| L | | | | |

International application No.

PCT/AU2004/000336

| Sin | n | nl | em | en | tal | Box |
|-----|---|----|------|----|-----|-----|
| υu | | ~ | CITY | ~ | | DUA |

(To be used when the space in any of Boxes I to VIII is not sufficient)

Continuation of Box No: II

Claims 27-44 and 50-52 are unduly broad and speculative. These claims refer to the use of agents that modulate the functional effective level of sphingosine kinase. There is no support for what is encompassed within the scope of the term "agent". Therefore it is not feasible to perform a meaningful and economical search on these claims.

Furthermore, these claims do not comply with rule 6.3 of the PCT. This rule refers to the claims defining the technical features of the invention. The invention lies in the determination that sphingosine kinase mediates the signalling pathway that regulates smooth muscle cell tone. Claims 27-44 and 50-52 are not limited to the agents when used to act directly on sphingosine kinase. The agents only have to be <u>capable of</u> modulating sphingosine kinase mediated signalling and then used to prepare a medicament. The medicament may then be used for any purpose. Thus the claims are not limited to the technical features of the invention and therefore the claims were not searched.